MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Inhibikase Therapeutics Shares 2011-2026 | IKT
Annual Shares Inhibikase Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98.3 M | 23.7 M | 6.03 M | 4.22 M | 18.2 M | 8.21 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98.3 M | 4.22 M | 26.4 M |
Quarterly Shares Inhibikase Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 172 M | 90.1 M | 90 M | 89.5 M | 69.4 M | 8.88 M | 7.54 M | 6.34 M | 6.19 M | 5.34 M | 5.23 M | 4.59 M | 4.22 M | 4.22 M | 4.22 M | 25.2 M | 25.2 M | 25.1 M | 12.2 M | 10.1 M | 10.1 M | 8.2 M | 8.18 M | 8.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 172 M | 4.22 M | 29.2 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
38.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
4.73 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Adagene
ADAG
|
59 M | $ 3.94 | -1.5 % | $ 232 M | China |
 |
Coherus BioSciences
CHRS
|
117 M | $ 1.65 | -0.6 % | $ 193 M | USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 31.7 | 0.16 % | $ 2.11 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
242 M | $ 93.44 | 0.47 % | $ 22.6 B | Germany |
 |
AstraZeneca PLC
AZN
|
1.55 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
9.34 B | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
93.4 M | $ 2.78 | 0.72 % | $ 260 M | Israel |
 |
Abcam plc
ABCM
|
229 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
98.5 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
54.9 B | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
45.7 M | $ 0.76 | -2.25 % | $ 34.7 M | Israel |
 |
Esperion Therapeutics
ESPR
|
208 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.9 M | $ 31.86 | -1.67 % | $ 857 M | USA |
 |
Affimed N.V.
AFMD
|
120 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
12.9 M | $ 20.77 | -3.26 % | $ 269 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
63.9 M | $ 2.57 | -4.81 % | $ 164 M | USA |
 |
Celyad Oncology SA
CYAD
|
22.6 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
66.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.34 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Grifols, S.A.
GRFS
|
680 M | $ 7.98 | -0.87 % | $ 5.42 B |  Spain |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Hutchison China MediTech Limited
HCM
|
858 M | $ 11.23 | -4.18 % | $ 9.64 B | China |
 |
Heron Therapeutics
HRTX
|
167 M | $ 0.89 | -1.97 % | $ 148 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
2.19 M | - | -4.36 % | $ 27 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.03 M | $ 9.9 | -6.87 % | $ 89.4 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
59.3 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
338 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
14.3 M | $ 14.9 | 0.61 % | $ 214 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
3.17 M | - | 5.93 % | $ 314 M | Canada |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 56.38 | 5.32 % | $ 5.07 B |  Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |